CDC’s Zika RT-PCR Test Wins Emergency Approval For Use In CLIA Labs
This article was originally published in The Gray Sheet
Executive Summary
FDA has approved an emergency-use authorization for a molecular-based Zika virus diagnostic developed by the Centers for Disease Control and Prevention, but the test is limited to use in CDC labs and Clinical Laboratory Improvement Amendments (CLIA) labs, and comes with a long list of conditions for use.
You may also be interested in...
CDC Whistleblower Says Test Misses Too Many Zika Cases; US Special Counsel Calls For Review
The US CDC-promoted Trioplex Zika virus test that won an FDA emergency-use authorization in March is nearly 40% less sensitive than a rival CDC Zika test called Singleplex, a CDC microbiologist whistleblower told superiors in April. A review of his complaints by HHS and CDC did not substantiate that, and CDC demoted him. The US Special Counsel sent a letter to the White House this week asking for further review.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.